Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK
This article was originally published in The Pink Sheet Daily
Executive SummaryDanish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.
You may also be interested in...
GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.